Core Viewpoint - The biopharmaceutical company Invivyd (IVVD) experienced a significant stock price drop of 18% following the announcement of a $50 million securities offering aimed at funding clinical projects, including research on monoclonal antibody therapies for long COVID [1] Group 1 - Invivyd's stock price fell by 18% in early trading on Thursday [1] - The company announced a securities offering to raise $50 million [1] - The funds will be used to support clinical projects, specifically research on monoclonal antibody therapies for long COVID [1]